A wave of fresh research is reshaping how doctors treat metastatic colorectal cancer, the deadly form of colon cancer that has spread beyond the colon. A Chinese Phase II trial found that a three‑drug cocktail—irinotecan, the oral chemotherapy TAS‑102, and the blood‑vessel blocker bevacizumab—gave patients who had their primary tumor removed a clear survival edge when used after first‑line therapy failed. In a separate study, patients whose tumors have a high‑microsatellite‑instability (MSI‑H) signature responded dramatically to a dual‑immunotherapy regimen of nivolumab plus ipilimumab, living longer without disease progression than those receiving standard chemotherapy. Meanwhile, a novel antibody‑drug conjugate called Temab‑A, which homes in on the c‑Met protein, showed manageable side‑effects and encouraging tumor shrinkage in heavily pre‑treated patients, especially when c‑Met levels were high. A new checkpoint inhibitor, SHR‑1701, combined with standard chemotherapy and bevacizumab, produced over 30 % tumor reduction in about 60 % of participants, suggesting a powerful first‑line option. On the surgical front, the ORCHESTRA trial confirmed that adding extensive tumor‑removing surgery to chemotherapy does not improve overall survival for patients with multi‑organ spread. Finally, researchers demonstrated that a simple blood test measuring circulating tumor DNA can predict how well patients will respond to first‑line chemo, offering a non‑invasive way to personalize treatment early on. Together, these advances bring renewed optimism that more patients with advanced colon cancer will live longer and enjoy better quality of life.
Read more